Category Archives: Mood Disorders
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial – The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30295-2/fulltext?rss=yes For us, this compares the UBC and MDA groups doing TMS in the Lower Mainland. Looks like both work equally well.
antidepressants for insomnia: the highest evidence thus far.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010753.pub2/epdf/abstract basically trazodone and doxepin are reasonable alternatives to z drugs
Chief complaint: Homicidal. Assessing violence risk | MDedge Psychiatry
https://www.mdedge.com/psychiatry/article/164162/chief-complaint-homicidal-assessing-violence-risk?oc_slh=a195008f33c4dd0dfa3c16ad9377076b1fbb3e1fab07e5a2e358c01ae920b082&utm_source=News_CPN_eNL_052518_F&utm_medium=email&utm_content=Is your patient likely to become violent?
POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes
Begin forwarded message: From: “Joule – a CMA Company” <cma.ca> Subject: POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes Date: May 15, 2018 at 4:00:03 AM PDT To: “Joris Anton Josef Wiggers” <joriswiggers> Reply-To: cma.ca View the Web version POEMs Research Summaries Your daily update for […]
Read More »
Intranasal Ketamine Succeeds for Resistant Depression
https://www.medscape.com/viewarticle/896510?nlid=122292_329&src=WNL_mdplsnews_180511_mscpedit_psyc&uac=27343DV&spon=12&impID=1630260&faf=1#vp_3 Timeline for S-ketamine intranasal spray, (Janssen), could file for product release by end of the year. Great hype. Low side effects. Good Phase 3 trial data released this month. We are hopeful to use it within 1 year? Game changer? Biggest psychopharma intro in 50 years? Lots of hype…
ECT Can Be Considered Earlier for Severe Depression, Expert Says | Psychopharmacology
https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp11a3 This is a landmark study for treatment of depression: They are now moving the benchmark to third line treatment for ECT; that is, after two failed trials of two antidepressants or one antidepressant and one psychotherapy, patient would go on to ECT. This is very aggressive, but the projected models show distinct improvement in […]
Read More »
